Inclusion Criteria (Healthy Volunteers):  Subject is male or female 18 to 55 yrs old Subject has a BMI 18 to 32 kg/m^2 Female and male subjects must use effective method of birth control Female subjects must have negative pregnancy test prior to first dose of study drug Subject must not have any clinically significant eye abnormality Subject must not have any clinically significant history or presence of ECG findings Subject must be in good general health  Inclusion Criteria (PA or MMA Patients):  Patient is male or female 18 to 55 yrs old Patient has a BMI 18 to 32 kg/m^2 Female and male patients must use effective method of birth control Female patients must have negative pregnancy test prior to first dose of study drug Patient must not have any clinically significant eye abnormality Patient must not have any clinically significant history or presence of ECG findings Patient must have confirmed PA or MMA diagnosis Patient with MMA must have elevated plasma MMA levels Patient is willing to provide access to medical records for the last 6-12 months of care prior to study initiation Patient is on consistent disease management and treatment regimen is stable for at least 30 days prior to study initiation.  Exclusion Criteria (Healthy Volunteers):  Subject has used prescription drugs within 4 weeks before first dose of study drug or over-the-counter medication within 7 days of the first dose of study drug Subject who has taken the COVID-19 vaccine, the last vaccine dose must be at least 14 days prior to first dose of study drug. Subject has abnormal laboratory test results Subject has a baseline eGFR <90 mL/minute Subject has positive result for Hepatitis B, Hepatitis C, or HIV Female subject is non-pregnant and non-lactating Subject is a smoker or has used nicotine or nicotine-containing products Subject has a history of alcohol or drug abuse within 12 months prior to first dose of study drug and/or has a positive result prior to dosing or throughout the study Subject has donated blood or blood products >450mL within 30 days prior to study drug dosing Subject has a history of relevant drug or food allergies Subject has received study drug in another investigational study within 30 days of dosing  Exclusion Criteria (PA or MMA Patients):  Patient has used prescription drugs within 4 weeks before first dose of study drug or over-the-counter medication within 7 days of the first dose of study drug that is not part of their PA or MMA disease management and treatment Patient who has taken the COVID-19 vaccine, the last vaccine dose must be at least 14 days prior to first dose of study drug. Patient has clinically significant abnormal laboratory test results unrelated to PA or MMA Patient has a baseline eGFR <60 mL/minute Patient has positive result for Hepatitis B, Hepatitis C, or HIV Female patient is non-pregnant and non-lactating Patient is a smoker or has used nicotine or nicotine-containing products Patient has a history of alcohol or drug abuse within 12 months prior to first dose of study drug and/or has a positive result prior to dosing or throughout the study Patient has donated blood or blood products >450mL within 30 days prior to study drug dosing Patient has a history of relevant drug or food allergies Patient has received study drug in another investigational study within 30 days of dosing Patient with PA has undergone prior liver and/or kidney transplant